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ABSTRACT
Objective: The objective is to present an update on the diagnosis and treatment of hypovitami-
nosis D, based on the most recent scientific evidence. Materials and methods: The Department 
of Bone and Mineral Metabolism of the Brazilian Society of Endocrinology and Metabology 
(SBEM) was invited to generate a document following the rules of the Brazilian Medical As-
sociation (AMB) Guidelines Program. Data search was performed using PubMed, Lilacs and 
SciELO and the evidence was classified in recommendation levels, according to the scientific 
strength and study type. Conclusion: A scientific update regarding hypovitaminosis D was pre-
sented to serve as the basis for the diagnosis and treatment of this condition in Brazil. Arq Bras 
Endocrinol Metab. 2014;58(5):411-33
Keywords
Vitamin D; cholecalciferol; PTH; osteoporosis; deficiency; insufficiency; diagnosis; treatment
RESUMO
Objetivo: Apresentar uma atualização sobre o diagnóstico e tratamento da hipovitaminose 
D baseada nas mais recentes evidências científicas. Materiais e métodos: O Departamento 
de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia 
(SBEM) foi convidado a conceber um documento seguindo as normas do Programa Diretrizes 
da Associação Médica Brasileira (AMB). A busca dos dados foi realizada por meio do PubMed, 
Lilacs e SciELO e foi feita uma classificação das evidências em níveis de recomendação, de 
acordo com a força científica por tipo de estudo. Conclusão: Foi apresentada uma atualização 
científica a respeito da hipovitaminose D que servirá de base para o diagnóstico e tratamento 
dessa condição no Brasil. Arq Bras Endocrinol Metab. 2014;58(5):411-33
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INTRODUCTION
H ypovitaminosis D is highly prevalent and re­presents a public health problem in the entire 
world. Studies show an elevated prevalence of this di­
sease in several geographic regions, including Brazil. It 
can affect more than 90% of individuals, depending on 
the population studied (1).
Vitamin D is essential in functions related to bone 
metabolism, but it seems to be related in the patho­
physiology of many diseases. In children, vitamin D 
deficiency leads to growth retardation and rickets. In 
adults, hypovitaminosis D leads to osteomalacia, to 
secondary hyperparathyroidism and consequently, to 
an increase in bone resorption, favoring bone mass loss 
and the development of osteopenia and osteoporosis. 
Muscle weakness can also happen, which further con­
tributes to elevating the risk of fall and bone fractures 
among patients with low bone mass (2,3).
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The correct diagnosis of this condition and the 
identification of improvement or worsening factors can 
help the elaboration of more efficient strategies for the 
treatment of risk populations, such as the elderly and 
post­menopausal women.
This document represents the efforts of the Depart­
ment of Bone Metabolism of the Brazilian Society of 
Endocrinology and Metabology (SBEM) for the devel­
opment of recommendations based on evidence availa­
ble in the scientific literature regarding the diagnosis 
and treatment of this condition. The objective of this 
document is to respond daily questions and to be a 
guideline for endocrinologists and clinicians in the Bra­
zilian context.
MATERIALS AND METHODS
The elaboration of this guideline was motivated by the 
SBEM within its Practical Guidelines program. The 
model applied followed the Guidelines Program of the 
Brazilian Medical Association (AMB) and the Federal 
Council of Medicine (CFM). After the selection of 
collaborators, with a significant role and relevant publi­
cations in the area, clinical questions to be approached 
were elaborated.
The publication search was performed using Med­
Line­PubMed and SciELO­Lilacs. We used the Oxford 
Classification, which evaluates the study design and 
considers the best available evidence for each question, 
to categorize the recommendation level or evidence 
strength of each article (4,5). 
The levels of recommendation and evidence 
strength were reported as:
A: experimental or observational studies with bet­
ter consistency.
B:  experimental or observational studies with less 
consistency.
C:  case reports (non­controled studies).
D:  opinion lacking critical evaluation, based on 
guidelines, physiological studies or animal mo­
dels.
DEFINITION AND PHYSIOLOGY
1. What is vitamin D: a nutrient or a prohormone?
Although it is defined as a vitamin, conceptually it 
is a prohormone. In conjunction with the parathyroid 
hormone (PTH), it acts as an important regulator of 
calcium homeostasis and bone metabolism. 
It can be obtained from food sources, such as cod 
liver oil and from other fat­rich fish (salmon, tuna, 
mackerel), or from endogenous cutaneous synthesis, 
which represents the most important source of this “vi­
tamin” for the majority of human beings (2,3,6,7) (A). 
Table 1 shows some food sources of vitamin D (3).
Vitamin D can be found in the form of ergocalci­
ferol or vitamin D2 and cholecalciferol or vitamin D3 
(8). Vitamin D2 can be obtained from some yeast and 
plants, being produced for commercial use, through ir­
radiation of the ergosterol present in some mushrooms 
(8) (D). 
Figure 1. Photobiosynthesis of vitamin D.
7-dehidrocholesterol
Cholecalciferol or 
vitamin D or D
3
Ergocalciferol or 
vitamin D
2 25 hydroxilase
25(OH) vitamin D
1 a hydroxilase 
1,25 (OH)
2
D
3
24, 25(OH)
2 
D
3
Receptor
Skin
Ultra-Violet Rays
In the skin, the precursor is the 7­dehydrocholeste­
rol (7­DHC) (8,9). During sun exposure, UVB pho­
tons (ultraviolet B, 290­315 nm) penetrate the epi­
dermis and produce a photochemical fragmentation 
to originate pre­cholecalciferol. This intermediate is 
converted to vitamin D (or cholecalciferol) through a 
temperature­dependent isomerization (Figure 1).
Table 1. Vitamin D food sources
Food Portion Vitamin D content per portion
Wild salmon 100 g ~ 600-1,000 IU vitamin D
3
Fish farming salmon 100 g ~ 100-250 IU vitamin D
3
Canned sardine 100 g ~ 300 IU vitamin D
3
Canned mackerel 100 g ~ 250 IU vitamin D
3
Canned tuna 100 g ~ 230 IU vitamin D
3
Cod liver oil 5 mL ~ 400-1,000 UI vitamin D
3
Egg yolk 1 unit ~ 20 IU vitamin D
3
Fresh mushroom 100 g ~ 100 IU vitamin D
2
Sun dried 
mushroom
100 g ~ 1,600 IU vitamin D
2
Adapted from ref. 3.
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Cholecalciferol is transported to the liver by DBP 
(vitamin D binding protein). In the liver, there is the 
hydroxylation of carbon 25 (CYP27B1), forming the 
25­hydroxyvitamin D (25(OH)D), through a process 
which is not strictly regulated, since it happens without 
control, and depends on the combination of cutaneous 
and diet stocks of vitamin D (8).
After the liver step, 25(OH)D is transported to the 
kidneys by DBP, where it is converted to calcitriol or 
1,25­dihydroxyvitamin D [1,25(OH)2D] (Figure 1). 
This is the most active metabolite and it is responsible 
for stimulating intestinal calcium and phosphate absorp­
tion. The kidney hydroxylation is stimulated by PTH 
and suppressed by phosphate and FGF­23. Calcitriol 
production is strictly controlled by negative feedback, 
in a way to influence its own synthesis by the decrease 
of 1a­hydroxylase. It is responsible for accelerating its 
inactivation through the conversion of 25(OH)D to 
24,25(OH)2D. This mechanism reflects a direct action 
of 1,25(OH)2D in the kidneys, however there is still an 
inhibitory action on PTH production in the parathy­
roids (8,9). The 1a­hydroxylase can also be found in 
other cells and tissues, such as the skin, prostate, breast, 
intestine, lungs, pancreatic β cells, monocytes and para­
thyroid cells. The 1,25(OH)2D molecule can also be 
locally synthesized by these cells and tissues (8,9) (D).
The vitamin D receptor (VDR) belongs to the super­
family of nuclear receptors regulating the transcription 
factors of the steroid hormones, retinoic acid, thyroid 
hormones and vitamin D. After binding 1,25(OH)2D to 
VDR, it interacts with the retinoic acid receptor, form­
ing a heterodimeric complex (RXR­VDR), which then 
binds specific sequences of DNA, known as Vitamin D 
Responsive Elements (VDRE) (10,11). The main target 
organs for 1,25(OH)2D are the intestine, bones, para­
thyroid glands and kidneys. However, its receptors have 
been found in several other tissues (10,11) (D).
SBEM recommendation: food sources are scarce in 
vitamin D and humans depend mainly on the skin 
production catalysed by UVB sunlight exposure (Evi­
dence A).
2. What are the effects on bone metabolism?
SBEM recommendation: active vitamin D mo­
dulates PTH synthesis, increases intestinal calcium 
absorption, and improves bone mass and muscular 
function (Evidence A).
The best known and studied actions of vitamin D 
are related to bone metabolism, where it plays a cru­
cial role. It participates in intestinal calcium absorption, 
muscle function, modulation of PTH secretion and 
bone cell function.
Parathyroid cells express the 1a­hydroxylase en­
zyme, and can synthetize the active form of vitamin 
D (1,25(OH)2D) inside the cells using the 25(OH)D 
serum pool (12) (B). In hypovitaminosis D, due to a 
minor intracellular synthesis, there is a secondary hy­
perparathyroidism, which is associated to an increase 
in bone resorption (2,13­16) (B), besides the fact that 
the circulating levels of 1,25(OH)2D are, generally, 
normal. There is an inverse correlation between PTH 
and 25(OH)D, described in children (17) and the el­
derly (2). Several cut off values for 25(OH)D for the 
PTH normalization have been published, the majority, 
being around 28 and 40 ng/mL (70 to 100 nmol/L) 
(2,18­23) (C). Other causes of secondary hyperpara­
thyroidism also have to be investigated, such as chronic 
kidney disease (creatinine clearance below 60 mL/
min), Paget’s disease, hungry bone syndrome and the 
calcium and vitamin D malabsorption syndromes (24).
Intestinal calcium absorption depends on the active 
vitamin D action in the duodenum, through a transcellu­
lar saturable process, whose stimulus leads to the synthe­
sis of proteins such as calbindin­D9K (CaBP­9k) and the 
epithelial apical channel TRPV6 (13,14) (D). However, 
there is evidence that the non­saturable transport, which 
happens with part of calcium absorption in the human 
ileum is also vitamin D sensitive (25). According to He­
aney and cols., individuals with 35 ng/mL of 25(OH)D 
presented higher absorption than those with 25 ng/mL 
(26) (B). Increase of calcium absorption with increasing 
dose of vitamin D3 or serum 25(OH)D was recently ob­
served, but there is no evidence of what the minimum 
value of 25(OH)D to ensure calcium absorption from 
the intestine in the range of 16­52 ng/mL evaluated in 
the study (27).
Population studies correlated positively vitamin D 
concentration with bone mass, mainly of the hip, but 
with 25(OH)D cut off points varying from 12 to 36 
ng/mL (30­90 nmol/L) (28­30) (C).
The muscle tissue expresses vitamin D receptors 
(13) and, clinically, muscle weakness and myopathy 
are observed in patients presenting severe vitamin D 
deficiency. Dhesi and cols., observed that the number 
of falls is higher among the elderly when they present 
the vitamin D deficiency (31) (C). The administration 
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of 800 IU of cholecalciferol for 12 weeks decreased 
in 49% the number of falls (32) (B). Cholecalciferol 
use is associated with the prevention of falls among the 
elderly with hypovitaminosis D, but not among those 
presenting normal serum values (33) (B).
In a meta­analysis of the main osteoporosis in­
tervention studies; Bischoff­Ferrari and cols. indi­
cated again 25(OH)D serum concentration above 
30 ng/mL (75 nmol/L) to be the most beneficial for 
health in general (A). Bone health, here represented 
by a better bone mineral density (BMD), decreased 
risk of fall and femural and non­vertebral osteopo­
rotic fractures, seems to be benefited by 25(OH)D 
concentrations equal to or higher than 30 ng/mL 
(75 nmol/L), concentrations around 36 ng/mL 
(90 nmol/L) being suggested as the most advanta­
geous (34­36). The same 25(OH)D values seem to 
benefit the muscle strength of lower limbs, which 
was evaluated by the TUG (Time Up and Go) test, 
where the individual is evaluated based on the time 
he needs to walk a distance equivalent to eight steps. 
Indivi duals presenting 25(OH)D in the range of 36 
to 40 ng/mL (90 and 100 nmol/L) seem to perform 
with higher speed. Evidence also suggests that higher 
25(OH)D values are associated with a lower risk for 
colorectal cancer and periodontal disease (36) (A).
Regarding the bone tissue, evidence suggests that 
1,25(OH)2D stimulates mineralization, through an 
indirect process that happens with the increase in in­
testinal absorption of the minerals which are incorpo­
rated into the bone matrix. Physiological concentra­
tions of calcitriol promote calcium mobilization to the 
bones, while the administration of large doses pro­
motes excessive bone remodeling. Osteoblasts present 
1,25(OH)2D receptor. This hormone modulates the 
gene expression of alkaline phosphatase and osteo­
calcin. Therefore, in the process of bone remodeling, 
1,25(OH)2D is important for bone formation and re­
absorption (37).
Priemel and cols. evaluated 675 bone biopsies and 
correlated the histomorphometry findings with serum 
25(OH)D concentration. The presence of bone mi­
neralization defects was only found in individuals with 
concentrations below 30 ng/mL (75 nmol/L) (38) 
(B).
The role of vitamin D in non­bone related end­
points, such as mortality, cardiovascular risk, cancer and 
autoimmune diseases is still controversial (39,40). 
DIAGNOSIS
3. How to define hypovitaminosis D?
SBEM recommendation: the analysis of the 25 
hydroxyvitamin D metabolite (25(OH)D) should be 
used for the evaluation of the vitamin D status of an 
individual (Evidence A).
There is a consensus that 25(OH)D (calcidiol) is 
the most abundant metabolite and the best indicator 
for the evaluation of vitamin D status (A), the indivi­
duals being classified as: deficient, insufficient of suf­
ficient in vitamin D (3,6,41,42). On the other hand, 
there is no consensus regarding the cut off value for the 
definition of “vitamin D sufficiency” (6,43,44).
The values discussed in the medical literature, 
based on populational studies, with emphasis on 
calcium homeostasis and bone health, vary from 20 
to 32 ng/mL (50 to 80 nmol/L) (26,43­47). Sev­
eral specialists agree that for correction of second­
ary hyperparathyroidism, reduction of the risk of fall 
and fractures and maximum calcium reabsorption, 
the best 25(OH)D cut off value is 30 ng/mL (75 
nmol/L) (6,41,46). Thus, serum concentrations be­
low 20 ng/mL (50 nmol/L) are classified as defi­
ciency; those ranging from 20 to 29 ng/mL (50 to 
74 nmol/L) as insufficiency and between 30 and 
100 ng/mL (75 and 250 nmol/L) as sufficiency. 
Therefore, many consider 25(OH)D serum con­
centrations below 30 ng/mL as hypovitaminosis D 
(3,41­43,48,49). These values were recognized by 
the Endocrine Society guideline, although they differ 
from the ones accepted (20 ng/mL) by the Institute 
of Medicine (IOM) (50) (B). In general population, 
there is no evidence of benefit in the measurement of 
25(OH)D due to the high cost, but according to the 
Endocrine Society, to maximize bone health; supple­
mentation is recommended for children up to 1 year 
with at least 400 IU/day; between 1 and 70 years, at 
least 600 IU/day while over 70 years old, 800 IU/
day (41).
SBEM recommendation: 25(OH)D concentrations 
above 30 ng/mL are desirable and should be the tar­
get for higher risk populations, because above this 
concentration, vitamin D benefits are more evident, 
especially regarding osteometabolic diseases and fall 
risk reduction (Evidence B).
Recommendations for the diagnosis and treatment of hypovitaminosis D
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4. What are the methodological implications for the 
plasma determinations of 25(OH)D?
SBEM recommendation: the methods based on 
chromatography are considered gold standard for 
the laboratory evaluation of 25(OH)D, although, 
automated immunometric assays can be used in the 
clinical practice taking into account the good correla­
tion with the method of excellence, besides the prac­
ticality and lower cost. However, the clinician should 
be aware of the possible mistakes caused by several 
interfering conditions, possibly leading to diagnostic 
classification errors (Evidence B).
Circulating 25(OH)D level is the best method to 
evaluate the individual vitamin D status. Neverthe­
less, there are controversies regarding the best method 
for 25(OH)D determination. Some factors should be 
considered when the levels of this vitamin are evalu­
ated, such as the lack of a precise physiological regula­
tory control (feedback), the variability of methods and 
standards, the inclusion of contaminant metabolites in 
the analysis, among others. Radioimmunoassays (RIA) 
used in the past underestimated the levels of 25(OH)D 
when the dominant levels were 25(OH)D2. RIA have 
been replaced by automated chemiluminescent immu­
noassays, resulting in higher concentrations and by im­
munoenzymatic assays which measure total 25(OH)D, 
a combination of vitamin D2 (25(OH)D2) and vitamin 
D3 (25(OH)D3 (51) (B).
The methods that do not employ direct immune 
detection are high performance liquid chromatogra­
phy (HPLC) coupled to mass spectrometry (LC­MS), 
which can distinguish individual levels of 25(OH)
D2 and 25(OH)D3. These are considered the gold 
standard for analysis and currently used as reference 
(52) (B). Both 1,25(OH)2D and 25(OH)D circu­
late predominantly bound to proteins and their con­
centration can be determined. However, to evaluate 
the vitamin D status, 25(OH)D total serum level is 
used, including both D3 and D2 forms. The results 
can be reported in nanograms per milliliter (ng/mL) 
or nanomol per liter (nmol/L). For conversion, you 
just need to multiply the value obtained in ng/mL by 
2.5, to obtain the value in nmol/L. Automated meth­
ods allow the use in clinical routines, they are fast 
and report 25(OH)D2 and 25(OH)D3 together, while 
LC­MS methods can distinguish between 25(OH)D2 
and 25(OH)D3, being useful, then, for the evaluation 
of the effectiveness of D2 supplementation, versus 
endogenous D3 production. These chromatographic 
methods, although more precise, are more laborious 
and expensive (53) (B).
SBEM recommendation: for conversion of 25(OH)
D concentration from ng/mL to nmol/L, the multi­
plication factor 2.5 is applied.
The accuracy of the measurements varies widely 
between laboratories and between different assays, 
and even when testing identical samples, this varia­
tion can achieve 17 ng/mL (53). The immunoassay 
requires the development of selective antibodies for 
25(OH)D2 and 25(OH)D3, which preferentially do 
not show cross reaction with any other metabolite. 
Matrix effects can still occur, caused by endogenous 
components that modify the binding of the antibody 
to the material to be analyzed. Metabolites with lower 
physio logical potential end up being included in the 
quantification, such as the 3­epimer of the 25(OH)
D, which can correspond to up to 5% of the to­
tal 25(OH)D. As its molecular weight is identical to 
25(OH)D, these are not separated by LC­MS. Finally, 
24,25 dihydroxyvitamin D (24,25(OH)2D), consid­
ered an inactive metabolite, can correspond to up to 
20% of the 25(OH)D measured, whereas some assays 
show 100% cross­reaction (51,54).
The use of a standard cut off value to evaluate vita­
min D status is problematic if applied to all laboratories 
and all methods, considering there are still differences 
on vitamin D extraction from its binding protein, cross 
reaction between 25(OH)D2, 25(OH)D3 and other 
metabolites, besides the lack of standardization (52,53) 
and for this reason, quality control tools, such as DE­
QAS (International Vitamin D External Quality Assess­
ment Scheme) were created, as an attempt to decrease 
the variation in data analysis (55).
The most used methods nowadays are competitive 
assays, based on specific antibodies and non­radioactive 
markers, the improvement in the comparison between 
results obtained from different methodologies being 
necessary. Whatever the method employed is a precise 
definition of the normality range is fundamental (56). 
It is also important to highlight that the intra­indivi­
dual variability can vary from 12.1 to 40.3% (57).
The clinical conditions that interfere with 25(OH)
D serum concentrations are highly dependent on envi­
ronmental factors and lifestyle, particularly UVB sun­
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light exposure. Polymorphisms in CYP27B1, which 
codes for 1a­hydroxylase, showed strong correlation 
with variations in 25(OH)D level. The vitamin D bind­
ing protein (DBP) is the main transporter for vitamin D 
metabolites, its phenotype helping predict 25(OH)D 
serum concentrations. Certain polymorphic forms can 
be more efficient for vitamin D binding, activation and 
metabolism, interfering with circulating levels. Genetic 
polymorphisms greatly contribute to the heterogeneity 
of clinical manifestations of hypovitaminosis D, espe­
cially among ethnic groups (51,58) (B).
EPIDEMIOLOGY
5. Which are the risk populations for hypovitaminosis 
D? What is the prevalence in Brazil?
SBEM recommendation: the analysis of 25(OH)
D concentration is not recommended for the gene­
ral population. It is recommended for specific groups 
belonging to populations at risk or for those with re­
levant clinical condition in which deficiency is suspec­
ted (Evidence A).
The Department of Bone and Mineral Metabolism 
from SBEM agrees with the guidelines published by 
the Endocrine Society, which does not recommend 
the 25(OH)D test for the general population con­
sidering the cost of this evaluation. The laboratory 
test is recommended for individuals under risk for hy­
povitaminosis D or for those with a relevant clinical 
condition. The candidates to be tested are the ones 
presenting the following conditions: rickets or osteo­
malacia, osteoporosis, history of falls and fractures in 
the elderly, obesity, pregnant and lactating women, 
patients with malabsorption syndromes (cystic fi­
brosis, inflammatory bowel disease, Chron’s disease, 
bariatric surgery), renal or liver insufficiency, hyper­
parathyroidism, medications interfering in vitamin D 
metabolism (anticonvulsants, glucocorticoids, anti­
fungal, antiretroviral, cholestyramine, orlistat), gran­
ulomatous diseases and lymphomas (41,59) (A). It is 
also useful for the evaluation of hypothesis of vitamin 
D intoxication.
Besides that, it is important to highlight that all the 
conditions that limit sunlight exposure can potentially 
cause hypovitaminosis D and can be added to the list of 
individuals in photoprotection regimen (60) (D) and 
religious garment users (veil, burqa, cassock and others) 
(61­63) (C).
Hypovitaminosis D is a world health problem and 
Brazil is part of this scenario, also presenting an elevated 
prevalence of hypovitaminosis D in the population (B). 
Table 2 presents some of the main Brazilian and inter­
national studies that included Brazil, published in the 
last decade. In general, in several regions of the country, 
the values indicate sub­optimum vitamin D concentra­
tions, verifying high prevalence of hypovitaminosis D in 
several age groups. The majority of the studies included 
mainly the elderly and post­menopausal women which 
are the populations at risk for osteoporosis (C). Ho­
wever, three studies involving adolescents showed high 
prevalence of hypovitaminosis D in this age group of 
the Brazilian population (64­66). The factors that seem 
to favor the presence of higher serum concentrations in 
our population are: younger age (64,67­69), commu­
nity life (70), the practice of outdoors physical activity 
(64,71), vitamin D oral supplementation (72), season 
of the year (spring, summer) (68­73), residence in sun­
ny beach areas (74,75) and in lower latitudes (76). 
Table 2. Prevalence of hypovitaminosis D in Brazil
Author, 
year
n Population Age 
(years) 
Average ± 
SD
Local, 
Latitude
25(OH)D (ng/
mL) Average 
± SD
25(OH)D 
(ng/mL) 
Cut off 
value
Prevalence
(%)
Vitamin D intake or oral 
supplementation
Saraiva, 
2005
(73)
and
2007 (70)
420
177
243
Elderly, > 65 years
Institutionalized
125 W and 52 M
From the community
168 W and 75 M
76 ± 9
79 ± 6
São Paulo, SP
23ºS
14.4 ± 9.2
19.6 ± 11.2
< 10
< 20
< 40
< 10
< 20
< 40
41
71
99
16
42
96
7% with oral supplementation: 
daily dose
125-1.000 IU
4% with supplementation
10% with supplementation
continuation
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Lips, 2006
(78)
151 Post-menopausal 
women with 
osteoprosis, > 41 
years, in ambulatorial 
follow up
67 Vitória, ES
20ºS
32.4 < 20
< 30
15
42
Values not mentioned
Maeda, 
2007 (68)
121 Volunteers,
17-33 years,
72 W and 49 M
24 ± 2 São Paulo, SP
23ºS
31.2 ± 13.2 < 28.8
< 40
50
75
Without supplementation
Silva, 
2008
(72)
180 Endocrinology 
ambulatorial patients, 
14-91 years,
165 W and 15 M
58 Belo 
Horizonte,
MG
19ºS
39.6 ± 16.8 < 14
< 32
0.8
42
27% with oral supplementation: 
varied doses
Peters, 
2008
(64)
136 Adolescents,
16-20 years, 
72 W and 64 M
18 Indaiatuba, SP
23ºS
29.2 ± 0.8 ≤ 10
≤ 30
0
62
Average daily intake
140 IU
Russo, 
2009
(77)
251 Post-menopausal 
volunteers with low 
bone mass, 50-85 
years
67 ± 6 Rio de 
Janeiro, RJ
22ºS
26 ± 10.4 <10
< 20
< 30
< 40
2
27
67
92
Without supplementation
Kuchuk, 
2009
(79)
1.486 Post-menopausal 
women with 
osteoporosis, 50-85 
years
- Latitude 
15°S-23ºS
28 ± 7.6 < 10
< 20
< 30
0.5
12.5
66
Values not mentioned
Lopes,
2009
(80)
415 Post-menopausal 
women with and 
without fractures
Without 
fracture: 
72.1 ± 4.4
with 
fracture: 
74.6 ± 5.8
São Paulo, SP
23ºS
Without 
fracture: 20.7 
± 10.7 
with fracture 
16.9 ± 8.2
< 30 Without 
fracture: 
82.3%  
with fracture: 
93.65%
Supplementation users were 
excluded
Maeda, 
2010
(71)
99 Physical exercise 
practitioners, 2 hours 
a week of outdoors 
physical activity,
52 W and 47 M
67 ± 6 São Paulo, SP
23ºS
31.6 ± 12.4 < 10
< 20
3
19
7% with oral supplementation: 
200-400 IU
Unger, 
2010
(67)
603 Volunteers:
employees and 
students from USP, 
18-80 years, 485 W 
and 118 M
47 ± 13 São Paulo, SP
23ºS
Median post 
winter: 21.4
Post summer: 
increase of 
10.6
< 30 77 Parameters not evaluated
Bandeira, 
2010
(74)
93 Healthy post-
menopausal women
65 ± 7 Recife, PE
8ºS
28.8 ± 14.8 < 20 24 Parameters not evaluated
Neves, 
2012
(75)
91 The elderly with SAH, 
> 60 years, 
81 W and 10 M
69 ± 7 João Pessoa, 
PB
7ºS
Adequate: 
44.8 ± 12.5
Non-
adequate: 24 
± 3.5
< 20
< 30
4
33
Without supplementation
Santos, 
2013
(66)
234 Adolescents 7-18 
years
13.0 ± 1.9 Curitiba, PR 
25º
Varied from 
20.8 to 22 in 
the studied 
tertiles
< 30
< 20
90,6
63,7
Without supplementation
Oliveira,
2013
(65)
160 Adolescents, 
15-17 years, 
71 W and 89 M
16 Juiz de Fora, 
MG
21ºS
- ≤ 10
≤ 30
1,3
70,6
Average daily intake 88 IU
Author, 
year
n Population Age 
(years) 
Average ± 
SD
Local, 
Latitude
25(OH)D (ng/
mL) Average 
± SD
25(OH)D 
(ng/mL) 
Cut off 
value
Prevalence
(%)
Vitamin D intake or oral 
supplementation
continuation
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Maeda, 
2013
(69)
591 Volunteers,
17-100 years,
388 W and 203 M 
Nursing 
homes: 
76.2 ± 9.0 
Community: 
79.6 ± 5.3
Exercise: 
67.6 ± 5.4
young: 23.9 
± 2.8
São Paulo, SP
23ºS
Nursing 
homes: 15.0 
± 11.9
community: 
19.8 ± 11.0
Exercise: 31.5 
± 12.4
young: 34.5 ± 
14.0
< 10
< 20
< 30
19
47
73
6% with oral supplementation: 
200-400 IU
Arantes,
2013
(76)
1.933 Post-menopausal 
women with low bone 
mass, 60-85 years 
67 ± 5 Latitude
8°S-33°S
27.2 ± 8.4 ≤ 30 68,3 Parameters not evaluated
Martini, 
2013
(81)
636 Adolescents, adults 
and the elderly
- São Paulo, SP
23ºS
M: 16.7
W: 19.2
< 20 - Intake varied from 108 to 140 IU/d
Cabral,
2013
(82)
284 Men, skin phototype 
evaluated
69.4 ± 6.5 Recife, PE
8ºS
28.0 ± 13.6 < 20
< 30
31,5
66,7
2,5% took supplements
M: men; W: women; IU: international units.
TREATMENT
6. How to treat hypovitaminosis D in patients who 
are at high risk for the deficiency?
SBEM recommendation: generalized vitamin D su­
pplementation is not indicated for the entire popu­
lation. The benefits of the vitamin D treatment are 
more evident in populations presenting high risk for 
the deficiency (Evidence A).
Current evidence does not support the concept of 
general population supplementation (41) (A). As the 
adequacy of vitamin D concentration in our popula­
tion is closely related to the cutaneous production, 
secon dary to sunlight exposure, individuals with low 
exposure represent the main population of deficient 
indivi duals. Therefore, a simple interview can bring 
important information on the probability of vitamin D 
deficiency in a specific individual.
The complementation of the daily needs, as well as 
the treatment of the deficiency should be performed for 
individuals with hypovitaminosis D risk (see Epidemi­
ology section) or those to whom sunlight exposure is 
prohibited, due to skin cancer, transplants or systemic 
lupus erythematosus (A). 
The most available vitamin D form for treatment 
and supplementation is cholecalciferol or vitamin D3 
and this is the metabolite that has been shown to be 
the most effective one. Ergocalciferol or vitamin D2 
can also be used as a supplement, however the studies 
show that, as its half­life is a little shorter than the one 
of D3, it should be used preferentially daily (83). Be­
sides that, some laboratory methods that test 25(OH)
D recog nize only 25(OH)D3, what can bring problems 
for the control of plasma levels when vitamin D2 is used 
for supplementation. Therefore, although supplemen­
tation and treatment can be done with both vitamin 
D metabolites, preference should be given to vitamin 
D3, due to the advantages on the maintenance of more 
stable concentrations.
The treatment doses vary according to the degree 
of deficiency and the target to be achieved. Apparent­
ly, 25(OH)D concentrations higher than 12 ng/mL 
would be sufficient to avoid rickets and osteomalacia, 
as well as to normalize intestinal absorption of calcium 
(84,85). However, to reduce fractures, concentrations 
above 24 ng/mL are necessary (86), while to avoid 
the development of secondary hyperparathyroidism, 
concentrations above 30 ng/mL are desirable (69). 
Therefore, especially during osteoporosis treatment, it 
Author, 
year
n Population Age 
(years) 
Average ± 
SD
Local, 
Latitude
25(OH)D (ng/
mL) Average 
± SD
25(OH)D 
(ng/mL) 
Cut off 
value
Prevalence
(%)
Vitamin D intake or oral 
supplementation
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is recommended that plasma 25(OH)D is kept above 
30 ng/mL.
As a practical rule, one can predict that, for every 
100 IU supplemented, an increase of 0.7 to 1.0 ng/mL 
is gained in the concentration of 25(OH)D (41). How­
ever, other studies show that this dose­response curve 
is not linear. 
In a study developed in Brazil, with an institutiona­
lized population, showing high prevalence of hypo­
vitaminosis D (40.4% with 25(OH)D < 20 ng/mL), 
supplementation with 7,000 IU/day, produced an 
average elevation of 7.5 ng/mL in 25(OH)D con­
centration after three months (87) and this elevation 
achieved a plateau around six weeks. However, as it 
has already been recognized by other authors, this in­
crease was more evident among those individuals with 
lower initial values (< 20 ng/mL), in whom the ave­
rage increase was 10.3 ng/mL after three months of 
treatment, while those showing 25(OH)D concentra­
tion above 20 ng/mL, increased on average only 5.18 
ng/mL. Besides that, 45% of the individuals still kept 
insufficient (30 ng/mL) and 10% still kept deficient (< 
20 ng/mL) at the end of three months of supplemen­
tation. This demonstrates that, for values lower than 
20 ng/mL, doses higher than 1,000 IU/day will be 
necessary if the target to be achieved is 30 ng/mL (B).
In a similar institutionalized population, Moreira­
Pfrimer and cols. demonstrated, in a randomized, dou­
ble blind prospective placebo controlled study, that an 
average dose of 3,700 IU/day of vitamin D3 for six 
months was able to take the treated group to average 
concentrations of 34.6 (variation from 20.9 to 48.4) 
ng/mL, while the placebo group kept in 20.7 (varia­
tion from 9.4 to 41.2) ng/mL (p < 0.0001). There was 
a significant increase in calcemia for the treated group, 
but no patient developed hypercalcemia (88) (A).
Those institutionalized and bedridden are a popula­
tion with elevated risk for deficiency. Mocanu and cols. 
evaluated the effect of the fortification of the bread roll 
with 320 mg of calcium and 5,000 IU of vitamin D 
on an institutionalized population for 12 months. It 
was possible to verify an effective increase in 25(OH)
D (initial average 11.4 ng/mL and final average 50.0 ng/
mL), with 92% of the individuals achieving concentra­
tions higher than 30 ng/mL. No individual developed 
hypercalcemia ou hypercalciuria. PTH concentrations 
were reduced during treatment and there was a signifi­
cant increase in BMD of the lumbar spine and proxi­
mal femur (89). However, when reevaluated, this same 
population, three years after removal of supplementa­
tion, it was verified that the benefits gained with vita­
min D supplementation had been lost (90).
In a population of post­menopausal women under­
going treatment for osteoporosis, followed in a specific 
outpatient clinic, Camargo (91) demonstrated that 
weekly doses higher than 7,000 IU (> 1,000 IU/day) 
are necessary to achieve vitamin D sufficiency (25(OH)
D > 30 ng/mL), which is in accordance with the 
propo sition of the Endocrine Society for the elderly at 
risk (Table 3). According to this Brazilian study, 73% of 
the patients, followed for at least three months in am­
bulatory directed to the treatment of osteoporosis were 
below the desired target concentration (> 30 ng/mL) 
(Figure 2). In the same study, a positive correlation was 
found between 25(OH)D concentrations and the fe­
mur BMD and a negative correlation with PTH (91).
Recommendations for the diagnosis and treatment of hypovitaminosis D
Table 3. Vitamin D daily maintenance doses recommended for the general 
population and the population at risk for the deficiency
Age groups  General population 
(IU)
Population at risk 
(IU)
0 – 12 months 400 400 – 1,000
1 – 8 years 400 600 – 1,000
9 – 18 years 600 600 – 1,000
19 – 70 years 600 1,500 – 2,000
> 70 years 800 1,500 – 2,000
Pregnant women 14 – 
18 years
600 600 – 1,000
Pregnant women > 18 
years
600 1,500 – 2,000
Lactating 14 – 18 years 600 600 – 1,000
Lactating > 18 years 600 1,500 – 2,000
Adapted from the nutritional tables of the Institute of Medicine and the Endocrine Society. 
Figure 2. Percentage of non-adequacy of vitamin D according to the 
plasma concentrations of 25-hydroxyvitamin D (25(OH)D) in a population 
of individuals presenting osteoporosis at a medical school teaching ward 
(91).
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In children and adolescents, the doses, apparently, 
do not vary much from the ones in the adults, with the 
exception of the first year of life (Table 3). Winzenberg 
and cols., in a meta­analysis involving six studies that 
evaluated vitamin D supplementation in healthy chil­
dren, were able to group 343 participants that received 
placebo and 541 participants that received vitamin D 
and the analysis suggested a benefit of the supplemen­
tation on the in lumbar spine bone mineral density and 
total body bone mineral content of those children that 
were previously deficient (92). Therefore, as already 
observed in other studies, the positive endpoints of the 
supplementation are always much more evident when 
the populations studied were initially deficient (A).
Vieth in a study done in Canada, tested two vitamin 
D3 doses, compared to placebo. The first dose was 1,400 
IU/week (or 200 IU/day), the same quantity recom­
mended at current nutritional tables from the Ministry 
of Health in Brazil. The second dose was 14,000 IU/
week, both groups being followed for 12 months. The 
group that received 1,400 IU/week did not present 
significant increase in 25(OH)D concentration, while 
the group receiving 14,000 IU obtained an increment 
of 15 to 30 ng/mL at the end of 12 months (93). Ta­
king from that and similar studies, an alteration on the 
vitamin D daily recommendation tables was proposed 
in several countries.
In 2011, the Institute of Medicine, in the USA, 
an organ that regulates the reference tables for daily 
recom mended intake (DRI) for the general population, 
increased the daily recommendation to 600 IU for in­
dividuals between the ages of 1 and 70, and to 800 IU 
for those older than 70 (Table 3) (50,94). However, 
the Brazilian nutritional table remains with the daily 
recommended intake of 200 IU, although several na­
tional studies have demonstrated that the typical meals 
of the Brazilian population are not a relevant vitamin D 
source (64,95), that we depend on cutaneous synthesis 
to obtain sufficiency and that the deficiency is present 
in all age and populational groups, especially among 
the elderly (70,74,76,80) (C).
Generally speaking, when 25(OH)D is lower than 
the target concentration (below 20 ng/mL), an at­
tack dose is necessary to replenish the body stocks. The 
most used scheme currently is to administer 50,000 
IU/week (or 7,000 IU/day) of vitamin D for six to 
eight weeks (41). In case the desired concentration 
of 25(OH)D is not achieved, a new cycle can be pro­
posed. As there can be some individual variation in the 
response to treatment, the reevaluation of the plasma 
values after each cycle is ideal, especially in the cases of 
more serious deficiencies, up to achieving the desired 
concentration. After this period, the maintenance dose 
should be defined and it varies according to the age 
group and concurrent conditions (Table 3). For the 
adults, maintenance doses vary between 400 and 2,000 
IU, depending on the sunlight exposure and skin tone. 
For the elderly, the recommended doses vary from 
1,000 to 2,000 IU/day or 7,000 to 14,000 IU/week. 
Obese individuals, presenting malabsorption condi­
tions or in use of anticonvulsants might need doses that 
are twice or three times higer (41) (A).
SBEM recommendation: doses recommended for 
the maintenance of vitamin D sufficiency are indi­
cated in table 3, varying for the different age groups. 
Howe ver, for deficiency correction, higher doses (at­
tack doses) are necessary (Evidence A).
Due to the fact that it is a liposoluble substance, vita­
min D is absorbed with fats and follows the enterohepatic 
circulation, meaning it is normally secreted through the 
gallbladder and reabsorbed in the small intestine. Thus, 
especially in cases of malabsorption, doses which are much 
higher than usual can be necessary in order to normalize 
25(OH)D concentrations. Besides that, for supplementa­
tion studies and in the daily practice it is possible to no­
tice some individual variation in blood concentrations of 
25(OH)D reached in response to a same dose of vitamin 
D, suggesting individuals might present different compe­
tencies in intestinal absorption or its metabolization (96). 
It seems there is no difference considering vitamin D ab­
sorption in relation to fasting or meal type (97).
SBEM recommendation: the risk of intoxication 
with the defined doses in this document is almost 
null (Evidence A). Special care must be taken when 
pharmaceutical compounding is used (Evidence D) 
and with patients that have diseases with anomalous 
production of 1,25 dihydroxyvitamin D by the tis­
sues, such as in granulomatous diseases and some 
lymphomas (Evidence B).
Vitamin D3, when administered as described above 
is very safe. Doses of up to 10,000 IU per day for five 
months did not induce signals of toxicity, which can be 
translated as hypercalcemia and hypercalciuria (98) (A). 
Toxic concentrations of 25(OH)D (> 90 ng/mL) are 
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difficult to achieve with these routine doses (99). In 
rare clinical situations, such as in some cases of granu­
lomatous diseases (sarcoidosis, tuberculosis and chronic 
fungal infections) and some lymphoma, activated mac­
rophages can locally produce 1,25(OH)2D in excess and 
induce hypercalcemia and hypercalciuria (B). Children 
with Williams syndrome are more predisposed to hy­
percalcemia. Therefore, under these conditions, supple­
mentation should be more criterious and follow fre­
quent monitoring of plasmatic and urinary calcium (41).
7. What are the differences between vitamin D2 and D3?
SBEM recommendation: vitamin D deficiency tre­
atment and supplementation can be done either with 
vitamin D3 (cholecalciferol) or with vitamin D2 (er­
gocalciferol), although the first metabolite presents 
some advantages over the second, due its commercial 
avaiability, for being more evaluated in clinical stu­
dies, for allowing more posologic formulations, pro­
moting more effective increases and for being identi­
fied by all laboratory methods (Evidence B).
Vitamin D sources are: sunlight exposure, diet and 
supplementation. The main difference between vitamin 
D2 (ergocalciferol) and vitamin D3 (cholecalciferol) is the 
source. In summary, vitamin D2 is the vitamin D from 
the plant sources, while the one from animal sources is 
in the form of vitamin D3. The D2 and D3 sources differ 
only due to the presence of an additional double bond 
and a methyl group incorporated to the long side chain 
of the biological form called D2 (100). The two forms 
present equivalent biological power and are activated 
in equally efficient ways by hydroxylases in humans. 
However, there is controversy on the bioequivalence of 
these formulations for supplementation. A meta­analysis 
evaluating only controlled and randomized studies that 
use vitamin D2 and D3 showed that vitamin D3 increased 
25(OH)D levels more significantly when compared to 
vitamin D2 (p = 0.001), the single or in bolus dose of 
vitamin D3 being better than D2 (p = 0.0002). However, 
this advantage was lost in daily supplementation (101) 
(A). Previous studies had already shown a small superi­
ority of vitamin D3 when administered in single dose, to 
maintain 25(OH)D le vels for longer time (102).
When the two formulations were compared in dai­
ly use for 25 weeks, it was observed that those u sing 
vitamin D2 presented 25(OH)D average concentra­
tions lower when compared to those that received 
D3, although, without altering PTH levels (103) (A). 
A recent study did not demonstrate difference in effec­
tiveness when higher 25(OH)D levels were found and 
also in sustained serum concentration of 1,25(OH)2D3, 
after 11 weeks of supplementation with 1,000 IU of 
vitamin D2 or D3 per day (104) (A). 
The same was observed in the treatment of children 
with rickets and controls, where there was a similar in­
crease in 25(OH)D and 1,25(OH)D levels with both 
formulations (105) (A). It is possible to conclude that 
both forms are equivalent in relation to daily supple­
mentation and that vitamin D3 presents superiority in 
relation to the maintenance of the 25(OH)D levels for 
single dose supplementation.
8. What is the difference between vitamin D and 
calcitriol?
SBEM recommendation: vitamin D active forms, 
such as calcitriol or alfacalcidol, should not be used 
when the objective is supplementation, or in the tre­
atment of vitamin D deficiency, because of their hi­
gher risk of side effects (Evidence A).
Calcitriol or 1,25(OH)2D is an active hormone, a 
final product of two vitamin D hydroxylations. Its en­
docrine action starts with renal production, finely con­
trolled by the activity of the 1a­hydroxylase enzyme. 
This enzyme, present in the epithelial cells or the proxi­
mal convoluted tubules is stimulated mainly by the PTH 
and is inhibited by FGF­23, among other less impor­
tant regulators. Circulating calcitriol itself also deviates 
its synthesis to an inactive product, the 24,25(OH)2D 
and, this way, protects the organism from its excess. 
The 1a­hydroxylase enzyme was identified in different 
tissues, what makes us believe there is some local pro­
duction of calcitriol, with autocrine and paracrine ac­
tions. Opposite to renal cells, where calcitriol produc­
tion is rigorously controlled, in these other tissues it is 
believed that production only depends on the presence 
of substrate (14,41). While all the systems of the orga­
nism are fully functioning, the recommendation is for 
the supplementation and treatment of the deficiency to 
be done with vitamin D itself, allowing tissues to pro­
duce their necessities, controlled by local or hormonal 
mechanisms, in the case of renal tubular cells. The use 
of calcitriol should be reserved for special situations, 
such as in chronic kidney insufficiency, in type 1 and 
type 2 vitamin D dependent rickets and in hypophos­
phatemic rickets, or in cases of extreme malabsorption. 
The use of calcitriol presupposes a much more rigorous 
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control of calcemia and calciuria, because hypercalce­
mia can frequently occur (14,41) (A).
9. How to do supplementation in special cases?
a) In chronic kidney disease
The patient with chronic renal disease presents higher 
risk for vitamin D deficiency. In renal disease, PTH con­
centrations also correlate with circulating 25(OH)D 
levels (A). Therefore, it is believed that vitamin D defi­
ciency contributes to the development of secondary hy­
perparathyroidism in chronic renal patients, independent 
on the renal calcitriol production. Nowadays it is known 
that several tissues, such as macrophages and osteoblasts 
have the capacity of producing active vitamin D (cal­
citriol) and that this synthesis depends on the subs trate, 
therefore, it is not strictly regulated as the renal synthe­
sis. Because of that, the treatment of the deficiency and 
the adequacy of the circulating levels of 25(OH)D is 
always recommended each time plasma concentrations 
are lower than 30 ng/mL (106­109). According to the 
opinion of the committee responsible for writing the 
treatment guidelines for osteomineral disease in chronic 
renal patients in Brazil, 25(OH)D quantification is rec­
ommended at the end of each cycle of attack doses, until 
the target concentration is achieved, and from then on, 
every six months (110) (D).
b) In the treatment of osteoporosis
A good part of vitamin D benefits on the risk of fractures 
observed in the literature has been associated with the 
concomitant use of calcium. Therefore, the adequacy 
of calcium intake, either through diet, or through the 
use of calcium salts, is part of any protocol for osteo­
porosis treatment. Recommended vitamin D doses are 
those capable of taking and maintaining plasma con­
centration to 30 ng/mL or above, avoiding, this way, 
the secondary hyperparathyroidism and the increase in 
bone resorption (111­113) (A). The non­adequacy of 
vitamin D concentration is considered one of the po­
tential failures in medicinal treatment of osteoporosis 
(significant BMD loss and fractures).
SBEM recommendation: for patients with osteopo­
rosis and increased risk of fractures, it is recommen­
ded that the 25(OH)D concentrations are maintained 
above 30 ng/mL for full benefits, for the prevention 
of secondary hyperparathyroidism, decreased risk of fall 
and improvement of BMD. To this end, daily doses be­
tween 1,000 and 2,000 IU are necessary (Evidence A).
c) In obesity and post-bariatric surgery
Obese patients present lower vitamin D concentration 
when compared to non­obese and are considered a 
population at risk for the deficiency (41) (A). Nowa­
days, bariatric surgery is a very used alternative to in­
duce weight loss in these individuals, possibly further 
aggravating this deficiency. Therefore, it is advisable 
to correct this condition prior to surgery. Santos and 
cols. demonstrated that women submitted to bariat­
ric surgery at least three years before, presented lower 
25(OH)D values when compared to normal paired 
controls, 77.1% of them presenting vitamin D insuf­
ficiency/deficiency and 41.7% presenting secondary 
hyperparathyroidism (Figure 3) (114). 25(OH)D con­
centrations correlated inversely with PTH (r = ­0,57, 
p < 0,05) and directly with bone remodeling markers 
(CTX and osteocalcin) which, together, can justify the 
increased risk for fracture observed in this population 
by other researchers (C). Depending on the surgical 
technique used and the degree of disabsorption pro­
moted, some individuals might have a lot of difficulty 
normalizing 25(OH)D and PTH concentrations, being 
necessary to follow these parameters and to consider a 
new attack dose or even higher maintenance doses that 
should be individually adjusted (D). In some cases, the 
orientation for frequent sunlight exposure and use of 
parenteral vitamin D are resources that can be neces­
sary (115­117).
Recommendations for the diagnosis and treatment of hypovitaminosis D
Figure 3. Prevalence of secondary hyperparathyroidism in a population of 
women submitted to bariatric surgery at least three years prior to the 
study enrollment. Different ranges of circulating 25(OH)D (114).
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SBEM recommendation: obese people are a popula­
tion at risk for deficiency and after bariatric surgery 
it is further aggravated, leading to a secondary hy­
perparathyroidism and an increased risk for fractures 
(Evidence A). 25(OH)D test in this situation is very 
useful for the titration of the daily vitamin D doses, 
which can be as high as ten times the routine ones 
(Evidence D).
d) Pregnancy
It is a critical period, because women are oriented 
to avoid sunlight exposure. Vitamin D deficiency in 
pregnant women was associated to low birth weight 
of the newborn, besides some late endpoints, such 
as low bone mass and cardiovascular risk markers in 
school age children. In a recent meta­analysis, Agha­
jafari and cols. analyzed 31 studies, including 18,869 
individuals and they concluded that the serum le vels 
of 25(OH)D are related to gestational diabetes, pre­
eclampsia, low birth weight newborn and bacterial 
vaginosis (118). In another meta­analysis, vitamin D 
supplementation showed positive effect on the low 
birth weight reduction (119) (A). The doses recom­
mended for supplementation in this period of life can 
be found in table 3.
When vitamin D deficiency is suspected, the treat­
ment with higher doses is still indicated, but daily doses 
are preferable. The 25(OH)D concentration in the 
newborn shows high correlation with the one found in 
the mother. The placenta presents the 1a­hydroxylase 
enzyme and therefore, has the capacity of converting 
25(OH)D to calcitriol. Apparently, this production is 
not strict controlled as that what happens in renal tu­
bules, and depends only on the amount of substrate 
(41) (C). For this reason, the recommendation during 
pregnancy is to avoid weekly or monthly doses. 
SBEM recommendation: for pregnant women pre­
senting deficiency risk, treatment brings benefits for 
the mother (Evidence B) and the newborn (Evidence 
A). Daily doses of vitamin D are recommended dur­
ing pregnancy and weekly or monthly higher doses 
should be avoided, because the placental production 
of calcitriol is substrate­dependant (Evidence C).
10. When should active vitamin D analogues be used?
SBEM recommendation: vitamin D analogues can 
be used to suppress PTH concentrations in patients 
with hyperparathyroidism secondary to chronic kidney 
disea se (CKD), the indication and the dose depending 
on the CKD stage and the PTH level (Evidence A). 
There is no superiority of the analogues currently avai­
lable in Brazil in comparison with cholecalciferol and 
calcitriol for the prevention of fractures (Evidence B). 
The analogues are not recommended for the preven­
tion of cancer (Evidence B).
Active vitamin D analogues are synthetic sub­
stances that directly bind the vitamin D receptor 
(VDR). They present different selectivity to the para­
thyroid cells, depending on its chemical structure, 
calcitriol (1,25(OH)2D3) shows smaller selectivity, 
promoting more side effects such as hypercalcemia, 
hyperphosphatemia and vascular calcifications. More 
selective compounds such as paricalcitol (19­nor­
1a,25(OH)2D2), maxacalcitol (22­oxa­1a,25(OH)2D3) 
and doxercalciferol (1a(OH)D2) and eldecalcitol 
(1a,25(OH)2­2β­(3­hydroxypropyloxy)D3) and doxer­
calciferol (1a(OH)D2) and eldecalcitol (1a,25(OH)2­
2β­(3­hydroxypropyloxy)D3) promote less adverse ef­
fects. Doxercalciferol and the alfacalcidol require liver 
25­hydroxylation to become active (120) (A).
a) Use in secondary hyperparathyroidism
The analogues are classically used to suppress PTH 
levels in patients with secondary hyperparathyroidism 
(SHPT) and chronic kidney disease (CKD). In CKD 
there is an increase in PTH levels, secondary to an alter­
ation of the regulation of the fibroblast growth factor 
(FGF­23) in the PTH­vitamin D axis and the decrease 
of calcitriol production due to CKD itself. The suppres­
sion of PTH levels in patients in stages 3­4 of CKD is 
more than 40% in 90% of the patients (121,122) (A).
The dose used is variable depending on the CKD 
stage, if the patient is undergoing dialysis or not and 
also on the serum PTH concentration. In CKD stages 
3­5, the ideal PTH levels are not defined yet, other 
PTH increasing factors having to be discarded. Hypo­
calcemia, vitamin D deficiency and hyperphosphatemia 
should be corrected initially. If PTH levels remain ele­
vated and progressively increasing, the use of analogues 
such as calcitriol, should be considered. In CKD stage 
5D with elevated and sustained PTH levels, the recom­
mendation is to maintain PTH levels between two and 
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nine times the upper limit of normality. There is no 
consensus on the doses of doxercalciferol and paricalci­
tol, some studies calculated the dose in relation to the 
initial PTH value dividing it by 80 to 120, to minimize 
the excessive suppression of PTH or hypercalcemia and 
hyperphosphatemia (106) (B).
The use of vitamin D analogues minimizes bone loss 
in CKD due to the suppression of PTH levels and pre­
vents bone remodeling reduction, due to the effect on 
the differentiation of normal osteoblasts and inhibition 
of osteoclastogenesis. However, the concern with the 
excessive suppression, which would lead to adynamic 
bone disease persists (122) (B).
Several studies have demonstrated benefit on the 
survival of patients undergoing dialysis treated with cal­
citriol or vitamin D analogues. Besides that, there is 
a smaller risk of progression for terminal renal disease 
and an increase in the survival in patients with CKD 
stages 3­4 (123,124) (B). There is doubt in relation 
to the benefit of vitamin D active analogues, compared 
to placebo, in relation to fractures, quality of life, hos­
pitalizations, muscle function and fall in these patients 
(125,126) (A).
The most selective analogues, compared to calci­
triol, demonstrate lower mortality, lower number of 
hospitalizations and lower duration of each hospitali­
zation per year (124) (B). Doxercalciferol, similar to 
paracalcitol, presents higher benefit in relation to sur­
vival, when compared to calcitriol. A dose­response was 
observed in the benefit when the levels of PTH were 
adjusted according to vitamin D (127) (B).
The use of analogues to avoid the evolution of ne­
phropaty in diabetic patients is discussed, although 
the results are still conflicting, using microalbuminu­
ria and albuminuria as markers. Results from VITAL 
study are awaited for a more definitive observation 
(120,128,129) (B).
b) Fracture prevention
The relationship between vitamin D levels with falls 
and fractures has been described, also as a significant 
linear predictor of major osteoporotic fractures in ten 
years (130) (B). A recent meta­analysis demonstrated 
a modest decrease in the prevention of fractures with 
the use of 1,25(OH)2D3 (calcitriol) and 1a­hydroxy­
vitamin D3 (alfacalcidol), similar to that obtained using 
doses higher than 700 IU/day of vitamin D3 (35) (A). 
Eldecalcitol (1a,25­dihydroxy­2β­[3­hydroxypro­
piloxy] vitamin D3 is a new analogue of vitamin D 
active form, recently approved for the treatment of 
osteoporosis in Japan. Eldecalcitol presents a strong 
inhibitory effect on bone resorption and significantly 
increases bone mineral density. This drug showed a 
26% decrease in the incidence of new vertebral frac­
tures in three years and 71% decrease in the risk of wrist 
fracture, in comparison to alfacalcidol, but showed no 
bene fit against hip fracture. An increase in serum cal­
cium was observed, although hypercalcemia was only 
seen in 0.4% of patients (131) (A). Edelcalcitol com­
pared to alfacalcidol promoted better quality of life and 
decreased severity of vertebral fractures (125,126) (A).
NON-BONE ACTIONS OF VITAMIN D
11. What is the evidence for extra-skeletal effects of 
vitamin D?
SBEM recommendation: although observational 
studies show an association between low vitamin D 
concentration and alterations in several extra­skeletal 
systems,  in the moment it is still not possible to pro­
ve a cause­effect relationship (Evidence B).
Traditionally, vitamin D was associated only with cal­
cium metabolism functions. The possibility of existence 
of extra­skeletal effects occurred after the disco very of 
vitamin D receptor (VDR) in tissues not involved with 
calcium metabolism (e. g. skin, placenta, breast, pros­
tate, and colon cancer cells) and the identification of 
the enzyme 1a­hydroxylase in extra­renal tissues. The 
question to be discussed is the real biological meaning 
of the presence of VDR and 1a­hydroxylase in different 
tissues (132).
Nagpal and cols. (133) reported that 1,25(OH)2D3 
through its transcriptional activity was able to directly 
or indirectly regulate at least 200 genes. These genes are 
involved in the control of proliferation, apoptosis and 
angiogenesis in several tissues. The etiological connec­
tion between vitamin D deficiency and specific extra­
skeletal diseases still needs to be identified in humans. 
Findings using animal models, regarding the beneficial 
effects of 1,25(OH)2D3 suggest mechanisms that in­
volve similar human signaling pathways (134,135) (B). 
The main non­skeletal effects studied in the literature 
will be described here. 
a) Vitamin D and cardiovascular disease
Vitamin D deficiency was included as a new risk fac­
tor for cardiovascular diseases (CVD) based on obser­
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vational studies that demonstrate a strong association 
between vitamin D deficiency and mortality due to 
cardiovascular disease, the mechanism being unclear in 
the literature (136) (B). Potential hypothesis include 
the action in the regulation of genes involving renin 
production, proliferation of cardiac and vascular mus­
cle cells, negative regulation of reactive C protein and 
other involvement in other proinflammatory processes. 
Fiscella and Franker (137) showed that black indivi­
duals, presenting calcitriol levels in the lower quartile 
presented 40% increase in the risk of death from coro­
nary arterial disease (CAD) or stroke (B).
Serious vitamin D deficiency in patients with stabi­
lized CVD is related to 50% more deaths from stroke 
and three to five times more sudden death (138). On 
the other hand, another study, demonstrated that very 
high levels are associated with an increase in the risk of 
ischemic myocardial disease (139). An increased risk of 
systemic arterial hypertension and metabolic syndrome 
has been demonstrated when sub­optimum vitamin D 
levels are detected (140). Observational and cohort 
studies led to the potential vitamin D use as an anti­hy­
pertensive agent. Some studies demonstrated decreased 
levels of systolic blood pressure upon supplementation. 
However, larger studies were not able to prove these 
positive effects. Two prospective studies did not show 
reduction in cardiovascular mortality upon vitamin D 
supplementation (131). A meta­analysis presented 8% 
reduction in the mortality from all causes with mo dest 
doses (141). Nonetheless, a recent meta­analysis in­
cluding 51 studies, concluded that supplementation did 
not have a significant effect in the mortality (RR 0.96), 
CAD incidence (RR 1.02) and stroke (RR 1.05) (136). 
So far, there is no strong evidence for the screening of 
vitamin D deficiency in patients under risk for CVD, as 
well as patients with previous CVD. Good prospective 
studies are necessary for a better understanding of the 
efficacy of supplementation in the risk reduction of car­
diovascular disease (132­134) (B).
b) Vitamin D and diabetes
Epidemiological and observational studies demonstrate 
a potential involvement of vitamin D in the patho­
genesis of the inflammatory process and in the preven­
tion and control of both diabetes mellitus type 1 and 
type 2 (DM1 and DM2). Studies performed in animals 
and humans suggest that vitamin D can be a potential 
modifier of these diseases (142) (A). 
Animal studies demonstrate that immunomodula­
tory and antiinflammatory actions of vitamin D reduce 
autoimmune insulinitis in DM1. It seems to suppress 
the antigen capacity of macrophages, inhibit the matu­
ration of dendritic cells, modulate the development of 
CD4 lymphocytes and inhibit the production of cyto­
kines such as interferon (IFN) and interleukin­2 (IL­2). 
These cytokines are known for activate macrophages 
and cytotoxic T cells, that lead to the destruction of 
pancreatic cells (143).
In DM2, vitamin D acts reducing insulin resistance 
and increasing its secretion, through the modulation 
of the immune and inflammatory process. DM2 is as­
sociated to an increase in the levels of tumor necrosis 
factors a and β, C­reactive protein (CRP), plasminogen 
activating factor and interleukin­6 (142).
Epidemiological studies demonstrate that children 
with vitamin D deficiency present 2.4 times higher risk 
of developing DM1. In the EURODIAB study there 
was as a reduction in the risk of developing DM1 in 
33% among supplemented children (144) (B). The 
same way the maternal supplementation demonstrates a 
protective effect to the newborn. A meta­analysis con­
cluded that, childhood supplementation seems to be 
protective against the development of DM1 (130). In 
adults with the disease, a reduction in the insulin dose 
was seen with the calcitriol supplementation (145) (B).
In rats with vitamin D deficiency, after supplemen­
tation there was improved insulin secretion (146). Two 
large studies evidenced that the combined use of cal­
cium and vitamin D reduced the risk of DM2. In a 
dose­response analysis, DM2 risk was reduced in 4% at 
each increment of 4 ng/mL in the concentration of 
25(OH)D (147) (B). In a meta­analysis, it was con­
cluded that the insufficiency of calcium and vitamin D 
can negatively influence glycemia and that supplemen­
tation of both can be beneficial for the optimization of 
glucose metabolism (146­147) (B).
There is evidence suggesting that vitamin D has 
a role in the prevention and treatment of DM1 and 
DM2, through its action on the immune system, insu­
lin secretion and resistance. However, further studies, 
using larger populations, are necessary to better eluci­
date the mechanisms of action and the doses necessary 
to present the best benefits (132­134,148) (A).
c) Vitamin D and cancer
Epidemiological studies demonstrated a correlation 
between sunlight exposure and mortality due to some 
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types of cancer, as well as skin color seems to be related 
to an increase in the prevalence of colorectal, breast 
and prostate cancer (149) (B). The risk of development 
and death due to neoplasia is more elevated in places of 
higher latitude and this can be related to lower sunligh 
exposure. Women presenting vitamin D insufficiency 
show a higher risk of developing colorectal cancer when 
compared to women presenting sufficient vitamin D 
levels, although no benefit was observed in the use of 
vitamin D for prevention (150,151).
In tissues where 25(OH)D is available, there is 
paracrine production of 1,25(OH)2D3, which through 
binding to its receptor, VDR, regulates transcription 
of target genes, that act in the differentiation of nor­
mal and tumor cells. Epidemiological and pre­clinical 
studies suggest the action of vitamin D in cancer pre­
vention and treatment. Polymorphisms in the VDR 
gene are associated with an increased risk for the de­
velopment of neoplasias (150). Local production of 
1,25(OH)2D3 does not have any function in the con­
trol of calcium metabolism, but it presents autocrine 
and paracrine effects. In vitro, it is possible to observe a 
decrease in 1a­hydroxylase (CYP27B1) and in vitamin 
D receptor (VDR) as the tumor progresses, associated 
to an increase in 24­hydroxylase (CYP24A1), which is 
inactivating. In vitro and in vivo studies demonstrate 
the direct or indirect effect of 1,25(OH)2D3 and its 
analogues on proliferation, differentiation, apoptosis, 
angiogenesis, invasion and inflammation of malignant 
cells. Microarray studies show that 1,25(OH)2D3 in­
fluences the transcription of a great number of genes, 
mainly related to apoptosis control (149,152) (B).
Low vitamin D levels make the tissues more sensi­
tive to pro­carcinogenic events. Vitamin D analogues 
are not able to eradicate tumor cells, however they can 
be used as adjuvants in cancer treatment. It is believed 
that high doses of these substances are necessary for a 
real benefit to be observed, although it increases ad­
verse effects (153) (B).
A double­blind placebo controlled study deter­
mined that the use of 1,25(OH)2D3 in pre­leukemia 
showed promising results at the beginning, although 
it determined an increase in calcemia during the blastic 
crisis (154). In prostate cancer, the administration of 
2,000 IU/day resulted in PSA levels reduction, though 
the presence of severe hypercalcemia determined the 
end of the study (134).
Some non­hypercalcemic calcitriol analogues are as­
sociated with good prognosis in patients that present 
elevated VDR expression. However, the use of calcitriol 
and analogues for the treatment of cancer patients is 
so far uncertain. Most of the clinical studies were con­
ducted in patients with prostate cancer and patients 
with advanced cancer that do not respond to traditional 
therapies. Laboratory evidence indicates that calcitriol 
generates a biological response that results in the inhi­
bition of the neoplastic progress. However, large scale 
clinical studies are necessary to confirm the benefits of 
vitamin D use in neoplasias (155,156) (B).
d) Vitamin D and autoimmune disease
Vitamin D action on the immune system seems to be 
mediated by B and T lymphocytes. VDR is present in 
these cells. The molecule 1,25(OH)2D3 inhibits the pro­
liferation of T cells, suppresses the synthesis and prolif­
eration of immunoglobulins, prevents the formation of 
IFN­γ (interferon­γ) and IL­2 (interleukin­2); besides 
increasing the activity of suppressor T cells (TH2). In 
humans, there is epidemiological evidence of the impor­
tance of vitamin D in the immune system (157) (C).
Sunlight or vitamin D are environmental factors in 
the etiology of multiple sclerosis and can have a role 
together with class II MHC inherited factors. Epide­
miological studies suggest that adults with elevated vi­
tamin D levels present lower risk of developing multiple 
sclerosis. Women with high vitamin D intake have 42% 
less chance to develop this disease (134,158) (B).
Preliminary studies suggest that activated vitamin D 
can be an efficacious treatment for rheumatoid arthri­
tis. Treated mice showed decreased activity of the cell 
responsible for this disease. In humans, epidemiological 
studies also confirmed a negative association between 
the levels of vitamin D and the prevalence of the dis­
ease. Other autoimmune diseases that are being asso­
ciated with vitamin D are: autoimmune encephalitis, 
systemic lupus erythematosus, intestinal inflammatory 
disease and autoimmune thyroiditis. Additional studies 
are necessary for the confirmation of data, and the use 
of vitamin D for the prevention and treatment of auto­
immune diseases (155,156). 
e) Vitamin D and innate immunity
Recent studies suggest that vitamin D can modulate in­
nate immunity. Hypovitaminosis D can present a nega­
tive impact in infectious diseases. It has been observed 
that 1,25(OH)2D3 has an antimicrobial activity, includ­
ing Mycobacterium tuberculosis, through the stimula­
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tion of cathelicidin production (protein that acts on the 
destruction of pathological agents) (159).
A study that used elevated vitamin D doses, 600,000 
IU, in tuberculosis patients, demonstrated higher body 
weight increase and less residual disease in those who 
received the vitamin, in comparison to the controls. 
The patients that were deficient when they were en­
rolled in the study (25­hydroxyvitaminD < 20 ng/mL) 
showed a more significant increase in Mycobacterium 
tuberculosis induced IFN­γ (160) (A). 
A research with post­menopausal women who re­
ceived 2,000 IU of vitamin D per day, showed a 90% 
reduction in upper respiratory tract infections, when 
compared to those who received 400 IU per day (B). 
Some studies also demonstrate that lower vitamin D 
levels can be a risk factor for sepsis. Studies for bacterial 
vaginosis, skin infection and of the oral cavity are being 
developed (155).
f) Vitamin D and psoriasis
The active form of vitamin D is a powerful inhibitor 
of keratynocytes proliferation and can be safely used in 
non­malignant hyperproliferative diseases of the skin, 
such as psoriasis. Data from controlled randomized 
studies demonstrated that the active form is an effective 
and well­tolerated treatment in patients with chronic 
initial or moderate psoriasis plaques. The topic applica­
tion of 1,25(OH)2D3 or its analogue calcipotriol can 
be used as a first line treatment against psoriasis (161).
g) Vitamin D and respiratory diseases 
In children with asthma, the level of 25(OH)D seems to 
positively correlate with the control of the disease and 
the pulmonary function; and negatively with the use of 
corticoids. Few intervention studies, evaluating vitamin 
D supplementation with asthma exists in the literature 
(155,156,162). One of them demonstrated that 1,200 
IU per day in children was associated to 83% reduction 
in the risk of disease exacerbation. It is believed that the 
immunomodulating effects of vitamin D and the effects 
on the pulmonary function can be useful for the treat­
ment of respiratory diseases (163).
h) Vitamin D and physical and cognitive function of 
the elderly
In large populational studies, low vitamin D levels are 
associated with mobility reduction, worsening in mus­
cular function and this way, an increase in the risk of 
fall (132,156,164). Vitamin D receptors present high 
concentrations in several areas of the central nervous 
system. Epidemiological studies demonstrated that low 
ingestion of vitamin D is associated with a cognitive de­
cline, an increased risk for Alzheimer disease and de­
pression. The mechanism suggested for this association 
includes the formation and aggregation of β­amiloid 
fibers, a deregulation of the gabaergic system and an 
increase in the calcium influx in the neurons (165).
Vitamin D seems to be involved in physiological 
and possibly pathologic changes that follow aging. If 
the supplementation can have a positive impact in the 
aging process is still uncertain and long­term interven­
tion studies are necessary (133,134).
i) Vitamin D and obesity
Obesity is associated with a higher prevalence of vi­
tamin D deficiency, interpreted as a sequestration by 
the adipose tissue. In fact, when compared with non­
obese individuals, the necessary dose for the reposition 
of vitamin D is higher among the obese. Recent data 
suggest that low concentrations of 25(OH)D could 
predict an acceleration in the increase of fat mass and 
this way would be involved with an increase of obesity 
incidence (135­137). Sergeev and cols., are investigat­
ing the mechanism through which 1,25(OH)2D3 regu­
lates the apoptosis of adipocytes. Preliminary studies 
in rats suggest that the supplementation with elevated 
doses of calcium and vitamin D reduce the weight and 
fat mass in obese rats. Studies in humans are necessary 
for the evaluation of the efficiency of vitamin D in the 
treatment of obesity (166).
In recent meta­analyzes and systematic reviews, it 
was observed an association between 25­hydroxyvi­
tamin D and several non­skeletal outcomes in obser­
vational studies, but that was not seen in randomized 
controlled trials (RCTs) (40,151). The effects of vita­
min D in other tissues is still controversial.
CONCLUSIONS
Vitamin D food sources are scarce and humans depend 
mainly on cutaneous synthesis. Hypovitaminosis D is 
very frequent in our country. Laboratorial evaluation 
should be performed measuring 25(OH)D and the 
following should be considered individuals at risk for 
vitamin D deficiency: the elderly, osteoporosis patients, 
patients with history of falls and fractures, obese peo­
ple, pregnant and lactating women, patients making 
use of medications that interfere with vitamin D me­
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tabolism (glucocorticoids, anticonvulsants, antifungal 
drugs), patients with malabsorption syndromes, pri­
mary hyperparathyroidism, renal or liver insufficiency, 
granulomatous diseases and lymphomas.
The most adequate normality value taking bone 
benefits into consideration is 30 ng/mL. The factors 
that seem to favor the presence of higher serum con­
centrations in our population are: younger age, com­
munity life, practice of outdoor physical exercises, oral 
vitamin D supplementation, season of the year (spring, 
summer), residence in sunny beach areas and in lower 
latitudes.
The most available vitamin D form for treatment 
and supplementation is cholecalciferol or vitamin D3. 
For patients with osteoporosis and increased risk of 
fractures it is recommended that 25(OH)D concen­
trations are kept above 30 ng/mL for full benefits 
on the prevention of secondary hyperparathyroidism, 
decreased risk of fall and better impact on BMD. For 
this purpose, maintenance doses between 1,000 and 
2,000 IU are necessary. Vitamin D active forms, such 
as calcitriol or alfacalcidol should not be used when 
the objective is supplementation or in the treatment 
of vitamin D deficiency, because of their higher risk 
of adverse effects. Special considerations regarding 
pregnant and lactating women, patients with chronic 
kidney disease, obese people and those submitted to 
bariatric surgery.
Nowadays there is special interest in the research of 
extra­skeleton effects of vitamin D, due to observatio­
nal studies that demonstrated association between low 
vitamin D concentration and several endpoints with 
mortality, cardiovascular complications, diabetes, can­
cer, autoimmune diseases, cognitive function, among 
others. However, in the moment it is still not possible 
to prove a cause­effect relationship.
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